NCT06935136

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

A Single-Arm, Multicenter, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this is Single-Arm, Multicenter, Open-Label Clinical Study is to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection(Axi-cel) as First-Line Therapy of High-Risk Large B-Cell Lymphoma.

Conditions

• CAR-T Cell Therapy
• High-risk Large B-cell Lymphoma (LBCL)

Interventions

Type	Name	Description
DRUG	Axicabtagene Ciloleucel	A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Timeline

• Start date: 2025-04-30
• Primary completion: 2026-10-09
• Completion: 2028-04-09
• First posted: 2025-04-20
• Last updated: 2025-04-22

Locations

1 site across 1 country: China